Form 4: Akero Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, sold 619 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 13, 2024, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, sold 619 shares of Akero Therapeutics common stock.
• The sale was executed at a price of $28.33 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units, in accordance with the company's 'sell-to-cover' policy.
• Following the transaction, Rolph directly owns 182,558 shares of Akero Therapeutics common stock, which includes 505 shares acquired under the company's 2019 Employee Stock Purchase Plan on June 30, 2023.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sell-to-cover) by a company executive. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The sale was part of a pre-existing 'sell-to-cover' policy, indicating a standard procedure for managing tax obligations.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates that a high-ranking officer in the company sold shares.

Stakeholder Impact

• The sale of shares by an officer could be perceived negatively by some shareholders, although it is a common practice for covering tax obligations.

Key Dates